Q3 FY2026 · ended Sep 30, 2026 · Revenue $9.83M, +85.9% YoY · Filed Nov 5, 2026
Profound Medical Corp. (PROF) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $9.8 million and a net loss of $7.7 million. As of Sep 30, 2026 it held $33.3 million in cash and investments and $7.4 million in total debt.
Revenue
$9.83M
+85.9% vs year-ago quarter
Net income
$-7.72M
+3.2% vs year-ago quarter
Operating cash flow
$-5.01M
+47.9% vs year-ago quarter
Free cash flow
—
EPS
$-0.21
+19.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
36.63M
+21.3% vs year-ago quarter
Net cash
$25.98M
Q3 FY2026
Operating margin
-145.1%
TTM
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- PROF (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Ontario, Canada
- Headquarters
- Mississauga, Ontario, Canada
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1628808
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $9.8M | $2.5M | $5.3M | $6.0M | $5.3M |
| Operating income | -$7.8M | -$11.1M | -$8.0M | -$7.4M | -$8.9M |
| Net income | -$7.7M | -$9.5M | -$7.1M | -$8.2M | -$8.0M |
| Diluted EPS | -$0.21 | -$0.26 | $0.19 | $2.52 | -$0.26 |
| Operating cash flow | -$5.0M | -$11.3M | -$8.6M | -$6.6M | -$9.6M |
| Total assets | $58.2M | $62.4M | $73.5M | $77.5M | $42.3M |
| Total liabilities | $15.6M | $12.6M | $14.0M | $11.0M | $10.2M |
| Stockholders' equity | $42.5M | $49.8M | $59.4M | $66.4M | $32.1M |
| Cash and investments | $33.3M | $38.3M | $50.3M | $59.7M | $24.8M |
| Total debt | $7.4M | $7.4M | $7.5M | $4.7M | $4.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Nov 3, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 22, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 14, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 9, 2026 | Oct 9, 2026 |
All 288 Profound Medical Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.